Kiyoshi Itagaki1, Elzbieta Kaczmarek1, Woon Yong Kwon1,2, Li Chen1,3, Barbora Vlková1,4, Quanzhi Zhang1,5, Ingred Riça6, Michael B Yaffe6, Yan Campbell7, Michael F Marusich7, Ji Ming Wang8, Wang-Hua Gong8, Ji-Liang Gao9, Françoise Jung10, Garry Douglas10, Leo E Otterbein1, Carl J Hauser1. 1. Department of Surgery, Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA. 2. Department of Emergency Medicine, Seoul National University Hospital, Seoul, South Korea. 3. PLA General Hospital, Beijing, China. 4. Institute of Molecular Biomedicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia. 5. College of Nursing, Harbin Medical School, Daqing, China. 6. The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA. 7. mAbDx, Eugene, OR. 8. National Cancer Institute/National Institutes of Health, Frederick, MD. 9. National Institute of Allergy and Infectious Diseases/National Institutes of Health, Frederick, MD. 10. Polyphor LTD, Allschwil, Switzerland.
Abstract
OBJECTIVES: Trauma predisposes to systemic sterile inflammation (systemic inflammatory response syndrome) as well as infection, but the mechanisms linking injury to infection are poorly understood. Mitochondrial debris contains formyl peptides. These bind formyl peptide receptor-1, trafficking neutrophils to wounds, initiating systemic inflammatory response syndrome, and wound healing. Bacterial formyl peptides, however, also attract neutrophils via formyl peptide receptor-1. Thus, mitochondrial formyl peptides might suppress neutrophils antimicrobial function. Also, formyl peptide receptor-1 blockade used to mitigate systemic inflammatory response syndrome might predispose to sepsis. We examined how mitochondrial formyl peptides impact neutrophils functions contributing to antimicrobial responses and how formyl peptide receptor-1 antagonists affect those functions. DESIGN: Prospective study of human and murine neutrophils and clinical cohort analysis. SETTING: University research laboratory and level 1 trauma center. PATIENTS: Trauma patients, volunteer controls. ANIMAL SUBJECTS: C57Bl/6, formyl peptide receptor-1, and formyl peptide receptor-2 knockout mice. INTERVENTIONS: Human and murine neutrophils functions were activated with autologous mitochondrial debris, mitochondrial formyl peptides, or bacterial formyl peptides followed by chemokines or leukotrienes. The experiments were repeated using formyl peptide receptor-1 antagonist cyclosporin H, "designer" human formyl peptide receptor-1 antagonists (POL7178 and POL7200), or anti-formyl peptide receptor-1 antibodies. Mouse injury/lung infection model was used to evaluate effect of formyl peptide receptor-1 inhibition. MEASUREMENTS AND MAIN RESULTS: Human neutrophils cytosolic calcium, chemotaxis, reactive oxygen species production, and phagocytosis were studied before and after exposure to mitochondrial debris, mitochondrial formyl peptides, and bacterial formyl peptides. Mitochondrial formyl peptide and bacterial formyl peptides had similar effects on neutrophils. Responses to chemokines and leukotrienes were suppressed by prior exposure to formyl peptides. POL7200 and POL7178 were specific antagonists of human formyl peptide receptor-1 and more effective than cyclosporin H or anti-formyl peptide receptor-1 antibodies. Formyl peptides inhibited mouse neutrophils responses to chemokines only if formyl peptide receptor-1 was present. Formyl peptide receptor-1 blockade did not inhibit neutrophils bacterial phagocytosis or reactive oxygen species production. Cyclosporin H increased bacterial clearance in lungs after injury. CONCLUSIONS: Formyl peptides both activate and desensitize neutrophils. Formyl peptide receptor-1 blockade prevents desensitization, potentially both diminishing systemic inflammatory response syndrome and protecting the host against secondary infection after tissue trauma or primary infection.
OBJECTIVES:Trauma predisposes to systemic sterile inflammation (systemic inflammatory response syndrome) as well as infection, but the mechanisms linking injury to infection are poorly understood. Mitochondrial debris contains formyl peptides. These bind formyl peptide receptor-1, trafficking neutrophils to wounds, initiating systemic inflammatory response syndrome, and wound healing. Bacterial formyl peptides, however, also attract neutrophils via formyl peptide receptor-1. Thus, mitochondrial formyl peptides might suppress neutrophils antimicrobial function. Also, formyl peptide receptor-1 blockade used to mitigate systemic inflammatory response syndrome might predispose to sepsis. We examined how mitochondrial formyl peptides impact neutrophils functions contributing to antimicrobial responses and how formyl peptide receptor-1 antagonists affect those functions. DESIGN: Prospective study of human and murine neutrophils and clinical cohort analysis. SETTING: University research laboratory and level 1 trauma center. PATIENTS: Traumapatients, volunteer controls. ANIMAL SUBJECTS:C57Bl/6, formyl peptide receptor-1, and formyl peptide receptor-2 knockout mice. INTERVENTIONS:Human and murine neutrophils functions were activated with autologous mitochondrial debris, mitochondrial formyl peptides, or bacterial formyl peptides followed by chemokines or leukotrienes. The experiments were repeated using formyl peptide receptor-1 antagonist cyclosporin H, "designer" humanformyl peptide receptor-1 antagonists (POL7178 and POL7200), or anti-formyl peptide receptor-1 antibodies. Mouseinjury/lung infection model was used to evaluate effect of formyl peptide receptor-1 inhibition. MEASUREMENTS AND MAIN RESULTS:Human neutrophils cytosolic calcium, chemotaxis, reactive oxygen species production, and phagocytosis were studied before and after exposure to mitochondrial debris, mitochondrial formyl peptides, and bacterial formyl peptides. Mitochondrial formyl peptide and bacterial formyl peptides had similar effects on neutrophils. Responses to chemokines and leukotrienes were suppressed by prior exposure to formyl peptides. POL7200 and POL7178 were specific antagonists of humanformyl peptide receptor-1 and more effective than cyclosporin H or anti-formyl peptide receptor-1 antibodies. Formyl peptides inhibited mouse neutrophils responses to chemokines only if formyl peptide receptor-1 was present. Formyl peptide receptor-1 blockade did not inhibit neutrophils bacterial phagocytosis or reactive oxygen species production. Cyclosporin H increased bacterial clearance in lungs after injury. CONCLUSIONS:Formyl peptides both activate and desensitize neutrophils. Formyl peptide receptor-1 blockade prevents desensitization, potentially both diminishing systemic inflammatory response syndrome and protecting the host against secondary infection after tissue trauma or primary infection.
Authors: Elzbieta Kaczmarek; Carl J Hauser; Woon Yong Kwon; Ingred Riça; Li Chen; Nicola Sandler; Leo E Otterbein; Yan Campbell; Charles H Cook; Michael B Yaffe; Michael F Marusich; Kiyoshi Itagaki Journal: J Trauma Acute Care Surg Date: 2018-11 Impact factor: 3.313
Authors: Christian Weber; Sandra Kraemer; Maik Drechsler; Hongqi Lue; Rory R Koenen; Aphrodite Kapurniotu; Alma Zernecke; Jürgen Bernhagen Journal: Proc Natl Acad Sci U S A Date: 2008-10-13 Impact factor: 11.205
Authors: M Castro; T I Morgenthaler; O A Hoffman; J E Standing; M S Rohrbach; A H Limper Journal: Am J Respir Cell Mol Biol Date: 1993-07 Impact factor: 6.914
Authors: David A Dorward; Christopher D Lucas; Gavin B Chapman; Christopher Haslett; Kevin Dhaliwal; Adriano G Rossi Journal: Am J Pathol Date: 2015-03-17 Impact factor: 4.307
Authors: David A Dorward; Christopher D Lucas; Mary K Doherty; Gavin B Chapman; Emma J Scholefield; Andrew Conway Morris; Jennifer M Felton; Tiina Kipari; Duncan C Humphries; Calum T Robb; A John Simpson; Phillip D Whitfield; Christopher Haslett; Kevin Dhaliwal; Adriano G Rossi Journal: Thorax Date: 2017-05-03 Impact factor: 9.139
Authors: Ghee Rye Lee; David Gallo; Rodrigo W Alves de Souza; Shilpa Tiwari-Heckler; Eva Csizmadia; James D Harbison; Sidharth Shankar; Valerie Banner-Goodspeed; Michael B Yaffe; Maria Serena Longhi; Carl J Hauser; Leo E Otterbein Journal: JCI Insight Date: 2021-10-22